Treatment Outcomes in Patients with Carcinoma In Situ of the Larynx

Treatment Outcomes in Patients with Carcinoma In Situ of the Larynx

To compare survival endpoints in patients with laryngeal carcinoma in situ (L-CIS) who received definitive radiotherapy (RT) versus other modalities as first-line treatment and after disease recurrence. This is a retrospective study of patients with L-CIS treated between June 2001 and December 2021....

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The Laryngoscope 2024-09
Hauptverfasser: I Ghanem, Ahmed, Gilbert, Marissa, Lin, Chun-Hui, Keller, Christian E, Gardner, Glendon M, Mayerhoff, Ross, Siddiqui, Farzan
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title The Laryngoscope
container_volume
creator I Ghanem, Ahmed
Gilbert, Marissa
Lin, Chun-Hui
Keller, Christian E
Gardner, Glendon M
Mayerhoff, Ross
Siddiqui, Farzan
description To compare survival endpoints in patients with laryngeal carcinoma in situ (L-CIS) who received definitive radiotherapy (RT) versus other modalities as first-line treatment and after disease recurrence. This is a retrospective study of patients with L-CIS treated between June 2001 and December 2021. Survival outcomes (recurrence-free (RFS), invasion-free (IFS), laryngectomy-free (LFS), and overall survival (OS)) were compared between patients who had first-line RT versus non-RT modalities and for patients with recurrent disease who underwent second-line RT. A total of 85 patients with L-CIS were included (73 men [85.9%] and 12 [14.1%] women, median age of 65 [IQR: 55-74] years). Of these, 42 had first-line RT (49.4%) and 43 (50.6%) had non-RT treatment. After median follow-up of 4.8 (IQR: 2.8-9) years, patients in the first-line RT group had improved 2-year (94.2% [95% confidence interval (CI): 86.7-100] versus 41.7% [CI: 29.3-59.5]) and 5-year (90.6% [CI: 80.9-100] versus 27.5% [CI: 16.4-48.2]) RFS relative to non-RT recipients (p 
doi_str_mv 10.1002/lary.31786
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3109976440</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3109976440</sourcerecordid><originalsourceid>FETCH-LOGICAL-c176t-282f069e5277db91055f2c2931af722679489bec534983702c01fb64cc4f6d13</originalsourceid><addsrcrecordid>eNo9kMtKAzEUhoMotlY3PoBkKcLU3DNZyuClUKhgF-5CJk1oZC41yaC-vVOtrg785-M_hw-AS4zmGCFy25j4NadYluIITDGnuGBK8WMwHZe0KDl5nYCzlN4QwpJydAomVFFCKcFTUK2jM7l1XYarIdu-dQmGDj6bHMYswY-Qt7Ay0Yaubw1cdPAl5AH2Huatg8vxcvd5Dk68aZK7OMwZWD_cr6unYrl6XFR3y8JiKXJBSuKRUI4TKTe1wohzTyxRFBsvCRFSsVLVznLKVEklIhZhXwtmLfNig-kMXP_W7mL_PriUdRuSdU1jOtcPSVOMlJKCMTSiN7-ojX1K0Xm9i6Edn9UY6b0zvXemf5yN8NWhd6hbt_lH_yTRb33HZcc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3109976440</pqid></control><display><type>article</type><title>Treatment Outcomes in Patients with Carcinoma In Situ of the Larynx</title><source>Wiley Online Library Journals</source><creator>I Ghanem, Ahmed ; Gilbert, Marissa ; Lin, Chun-Hui ; Keller, Christian E ; Gardner, Glendon M ; Mayerhoff, Ross ; Siddiqui, Farzan</creator><creatorcontrib>I Ghanem, Ahmed ; Gilbert, Marissa ; Lin, Chun-Hui ; Keller, Christian E ; Gardner, Glendon M ; Mayerhoff, Ross ; Siddiqui, Farzan</creatorcontrib><description>To compare survival endpoints in patients with laryngeal carcinoma in situ (L-CIS) who received definitive radiotherapy (RT) versus other modalities as first-line treatment and after disease recurrence. This is a retrospective study of patients with L-CIS treated between June 2001 and December 2021. Survival outcomes (recurrence-free (RFS), invasion-free (IFS), laryngectomy-free (LFS), and overall survival (OS)) were compared between patients who had first-line RT versus non-RT modalities and for patients with recurrent disease who underwent second-line RT. A total of 85 patients with L-CIS were included (73 men [85.9%] and 12 [14.1%] women, median age of 65 [IQR: 55-74] years). Of these, 42 had first-line RT (49.4%) and 43 (50.6%) had non-RT treatment. After median follow-up of 4.8 (IQR: 2.8-9) years, patients in the first-line RT group had improved 2-year (94.2% [95% confidence interval (CI): 86.7-100] versus 41.7% [CI: 29.3-59.5]) and 5-year (90.6% [CI: 80.9-100] versus 27.5% [CI: 16.4-48.2]) RFS relative to non-RT recipients (p &lt; 0.001). OS and IFS were similar between groups. However, patients in the RT group had worse 2-year (94% [CI: 87-100] versus 98% [CI: 93-100]) and 5-year (82% [CI: 68-99] versus 98% [CI: 93-100]; p = 0.013) LFS. All 35 patients with recurrent L-CIS were successfully cured with second-line treatments (12 received RT [34.3%]), and no differences in any survival endpoints were seen in these patients based on first-line and second-line treatments. Although first-line RT for L-CIS led to improved recurrence-free survival compared with other modalities, second-line RT may be a particularly valuable option for recurrent CIS. 3 Laryngoscope, 2024.</description><identifier>ISSN: 0023-852X</identifier><identifier>ISSN: 1531-4995</identifier><identifier>EISSN: 1531-4995</identifier><identifier>DOI: 10.1002/lary.31786</identifier><identifier>PMID: 39323321</identifier><language>eng</language><publisher>United States</publisher><ispartof>The Laryngoscope, 2024-09</ispartof><rights>2024 The American Laryngological, Rhinological and Otological Society, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c176t-282f069e5277db91055f2c2931af722679489bec534983702c01fb64cc4f6d13</cites><orcidid>0000-0002-3262-4737 ; 0000-0002-3396-6763 ; 0000-0002-0801-340X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39323321$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>I Ghanem, Ahmed</creatorcontrib><creatorcontrib>Gilbert, Marissa</creatorcontrib><creatorcontrib>Lin, Chun-Hui</creatorcontrib><creatorcontrib>Keller, Christian E</creatorcontrib><creatorcontrib>Gardner, Glendon M</creatorcontrib><creatorcontrib>Mayerhoff, Ross</creatorcontrib><creatorcontrib>Siddiqui, Farzan</creatorcontrib><title>Treatment Outcomes in Patients with Carcinoma In Situ of the Larynx</title><title>The Laryngoscope</title><addtitle>Laryngoscope</addtitle><description>To compare survival endpoints in patients with laryngeal carcinoma in situ (L-CIS) who received definitive radiotherapy (RT) versus other modalities as first-line treatment and after disease recurrence. This is a retrospective study of patients with L-CIS treated between June 2001 and December 2021. Survival outcomes (recurrence-free (RFS), invasion-free (IFS), laryngectomy-free (LFS), and overall survival (OS)) were compared between patients who had first-line RT versus non-RT modalities and for patients with recurrent disease who underwent second-line RT. A total of 85 patients with L-CIS were included (73 men [85.9%] and 12 [14.1%] women, median age of 65 [IQR: 55-74] years). Of these, 42 had first-line RT (49.4%) and 43 (50.6%) had non-RT treatment. After median follow-up of 4.8 (IQR: 2.8-9) years, patients in the first-line RT group had improved 2-year (94.2% [95% confidence interval (CI): 86.7-100] versus 41.7% [CI: 29.3-59.5]) and 5-year (90.6% [CI: 80.9-100] versus 27.5% [CI: 16.4-48.2]) RFS relative to non-RT recipients (p &lt; 0.001). OS and IFS were similar between groups. However, patients in the RT group had worse 2-year (94% [CI: 87-100] versus 98% [CI: 93-100]) and 5-year (82% [CI: 68-99] versus 98% [CI: 93-100]; p = 0.013) LFS. All 35 patients with recurrent L-CIS were successfully cured with second-line treatments (12 received RT [34.3%]), and no differences in any survival endpoints were seen in these patients based on first-line and second-line treatments. Although first-line RT for L-CIS led to improved recurrence-free survival compared with other modalities, second-line RT may be a particularly valuable option for recurrent CIS. 3 Laryngoscope, 2024.</description><issn>0023-852X</issn><issn>1531-4995</issn><issn>1531-4995</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNo9kMtKAzEUhoMotlY3PoBkKcLU3DNZyuClUKhgF-5CJk1oZC41yaC-vVOtrg785-M_hw-AS4zmGCFy25j4NadYluIITDGnuGBK8WMwHZe0KDl5nYCzlN4QwpJydAomVFFCKcFTUK2jM7l1XYarIdu-dQmGDj6bHMYswY-Qt7Ay0Yaubw1cdPAl5AH2Huatg8vxcvd5Dk68aZK7OMwZWD_cr6unYrl6XFR3y8JiKXJBSuKRUI4TKTe1wohzTyxRFBsvCRFSsVLVznLKVEklIhZhXwtmLfNig-kMXP_W7mL_PriUdRuSdU1jOtcPSVOMlJKCMTSiN7-ojX1K0Xm9i6Edn9UY6b0zvXemf5yN8NWhd6hbt_lH_yTRb33HZcc</recordid><startdate>20240926</startdate><enddate>20240926</enddate><creator>I Ghanem, Ahmed</creator><creator>Gilbert, Marissa</creator><creator>Lin, Chun-Hui</creator><creator>Keller, Christian E</creator><creator>Gardner, Glendon M</creator><creator>Mayerhoff, Ross</creator><creator>Siddiqui, Farzan</creator><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-3262-4737</orcidid><orcidid>https://orcid.org/0000-0002-3396-6763</orcidid><orcidid>https://orcid.org/0000-0002-0801-340X</orcidid></search><sort><creationdate>20240926</creationdate><title>Treatment Outcomes in Patients with Carcinoma In Situ of the Larynx</title><author>I Ghanem, Ahmed ; Gilbert, Marissa ; Lin, Chun-Hui ; Keller, Christian E ; Gardner, Glendon M ; Mayerhoff, Ross ; Siddiqui, Farzan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c176t-282f069e5277db91055f2c2931af722679489bec534983702c01fb64cc4f6d13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>I Ghanem, Ahmed</creatorcontrib><creatorcontrib>Gilbert, Marissa</creatorcontrib><creatorcontrib>Lin, Chun-Hui</creatorcontrib><creatorcontrib>Keller, Christian E</creatorcontrib><creatorcontrib>Gardner, Glendon M</creatorcontrib><creatorcontrib>Mayerhoff, Ross</creatorcontrib><creatorcontrib>Siddiqui, Farzan</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The Laryngoscope</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>I Ghanem, Ahmed</au><au>Gilbert, Marissa</au><au>Lin, Chun-Hui</au><au>Keller, Christian E</au><au>Gardner, Glendon M</au><au>Mayerhoff, Ross</au><au>Siddiqui, Farzan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Treatment Outcomes in Patients with Carcinoma In Situ of the Larynx</atitle><jtitle>The Laryngoscope</jtitle><addtitle>Laryngoscope</addtitle><date>2024-09-26</date><risdate>2024</risdate><issn>0023-852X</issn><issn>1531-4995</issn><eissn>1531-4995</eissn><abstract>To compare survival endpoints in patients with laryngeal carcinoma in situ (L-CIS) who received definitive radiotherapy (RT) versus other modalities as first-line treatment and after disease recurrence. This is a retrospective study of patients with L-CIS treated between June 2001 and December 2021. Survival outcomes (recurrence-free (RFS), invasion-free (IFS), laryngectomy-free (LFS), and overall survival (OS)) were compared between patients who had first-line RT versus non-RT modalities and for patients with recurrent disease who underwent second-line RT. A total of 85 patients with L-CIS were included (73 men [85.9%] and 12 [14.1%] women, median age of 65 [IQR: 55-74] years). Of these, 42 had first-line RT (49.4%) and 43 (50.6%) had non-RT treatment. After median follow-up of 4.8 (IQR: 2.8-9) years, patients in the first-line RT group had improved 2-year (94.2% [95% confidence interval (CI): 86.7-100] versus 41.7% [CI: 29.3-59.5]) and 5-year (90.6% [CI: 80.9-100] versus 27.5% [CI: 16.4-48.2]) RFS relative to non-RT recipients (p &lt; 0.001). OS and IFS were similar between groups. However, patients in the RT group had worse 2-year (94% [CI: 87-100] versus 98% [CI: 93-100]) and 5-year (82% [CI: 68-99] versus 98% [CI: 93-100]; p = 0.013) LFS. All 35 patients with recurrent L-CIS were successfully cured with second-line treatments (12 received RT [34.3%]), and no differences in any survival endpoints were seen in these patients based on first-line and second-line treatments. Although first-line RT for L-CIS led to improved recurrence-free survival compared with other modalities, second-line RT may be a particularly valuable option for recurrent CIS. 3 Laryngoscope, 2024.</abstract><cop>United States</cop><pmid>39323321</pmid><doi>10.1002/lary.31786</doi><orcidid>https://orcid.org/0000-0002-3262-4737</orcidid><orcidid>https://orcid.org/0000-0002-3396-6763</orcidid><orcidid>https://orcid.org/0000-0002-0801-340X</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0023-852X
ispartof The Laryngoscope, 2024-09
issn 0023-852X
1531-4995
1531-4995
language eng
recordid cdi_proquest_miscellaneous_3109976440
source Wiley Online Library Journals
title Treatment Outcomes in Patients with Carcinoma In Situ of the Larynx
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T18%3A35%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Treatment%20Outcomes%20in%20Patients%20with%20Carcinoma%20In%20Situ%20of%20the%20Larynx&rft.jtitle=The%20Laryngoscope&rft.au=I%20Ghanem,%20Ahmed&rft.date=2024-09-26&rft.issn=0023-852X&rft.eissn=1531-4995&rft_id=info:doi/10.1002/lary.31786&rft_dat=%3Cproquest_cross%3E3109976440%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3109976440&rft_id=info:pmid/39323321&rfr_iscdi=true